Sentiment Summary
Recent Events
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
On June 16, 2026, the Annual General Meeting 2026 is scheduled; low impact expected as it is a routine corporate event, scheduled.
Medtronic is scheduled to report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026. This event is expected to have a medium impact as earnings reports typically drive significant price volatility scheduled.
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
On May 18, 2026, publication of the full-year results for the 2025/26 fiscal year is scheduled. The company expects growth to be at the lower end of guidance; high impact expected as earnings are a key market driver, expected.
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
CEO Jane Chao and CFO Scott Blumberg are scheduled to participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference; low impact estimated as conference participations typically provide incremental updates, scheduled.
Q1 2026 financial results are scheduled to be released after the market close; low impact estimated for the announcement of the reporting date, expected.
First quarter 2026 earnings release scheduled for May 7, 2026. Medium importance is estimated as earnings releases typically cause >5% price impact. Analysts project an EPS of $0.92, expected.
Q2 2025/26 earnings release. The company has guided for full-year organic growth of 10-13% and an EBIT margin of 12-14%. Importance is estimated as High based on the potential for significant market reaction to results and any guidance updates. The release is set for May 6, 2026, scheduled.
LivaNova First-Quarter 2026 earnings results scheduled for 2026-05-06; quarterly earnings releases typically result in significant price movements of >=10% scheduled.
Earnings releases are high-impact events with the potential to cause significant price volatility; first quarter 2026 financial results and conference call scheduled.
Integer Holdings is scheduled to release its Q1 2026 financial results on April 30, 2026, before the market opens, followed by a conference call. Analysts forecast EPS of $1.19 and revenue of $425.3 million. High importance is estimated due to the potential for significant price volatility typical of earnings releases. This event is scheduled.
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled
Alphabet reported Q1 2026 revenue of $109.9 billion and EPS of $5.11, significantly beating analyst estimates of $107 billion and $2.67, respectively. High importance is estimated due to the massive EPS beat which is expected to drive a >10% price impact, expected.
The company's antibody-drug conjugate (ADC) SYS6051 received approval from the US FDA on 2026-04-29 to commence clinical trials for advanced solid tumors, following a similar approval from China's NMPA in April 2026; Medium importance estimated due to the significant regulatory milestone, with positive impact expected.
Announced on 2026-04-29 that its self-developed Class 1 new drug, HS-10522 tablets, received two clinical trial approvals from China's NMPA for treating uncontrolled hypertension and primary aldosteronism. Medium importance is assigned as clinical approvals for new drugs typically impact price by >=5%.
Announced on 2026-04-29 that its B7-H3 targeted ADC, HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating advanced castration-resistant prostate cancer. Medium importance is assigned as Breakthrough Therapy Designation is a significant milestone likely impacting price by >=5%.
Announced an ongoing share buyback program on 2026-04-29, with multiple repurchases conducted throughout April 2026; low impact estimated for routine buyback, expected.
Announced that Mr. Tian Zhoushan and Mr. Li Dakui retired as directors of the company on 2026-04-29; low impact estimated for administrative change, expected.
Medtronic received U.S. Food and Drug Administration (FDA) approval for the Mosaic Neo mitral valve, its next-generation mitral bioprosthesis, on April 29, 2026.
Announced Q1 2026 results, with net profit attributable to shareholders of RMB 49.04 million, a 70.36% decrease year-over-year, while revenue increased by 15.17% to RMB 1.801 billion. Significant profit decline is likely to cause a price impact of 10% or more, expected.
Ivonescimab (PD-1/VEGF bispecific antibody) received multiple upgraded Class I recommendations in the 2026 Chinese Society of Clinical Oncology (CSCO) guidelines for Non-Small Cell Lung Cancer (NSCLC), strengthening its position as a preferred first-line treatment. Estimated price impact ≥10% due to major clinical guideline upgrade. Expected.
Reported Q1 2026 results on 2026-04-28, achieving a net profit of CNY 328.01 million, a significant turnaround from a net loss of CNY 254.14 million in the same period last year. Revenue grew 24.76% YoY to CNY 656.21 million. Estimated price impact >=10% due to significant financial turnaround and the release is scheduled.
On 2026-04-28, announced and open-sourced the 'SenseNova U1' series, a native unified model for understanding and generation based on NEO-unify architecture; estimated to have a market impact of at least 5% expected.
Q1 2026 results release on April 28, 2026, reporting a 6.93% YoY increase in revenue and a 13.87% YoY increase in net profit. Medium importance estimated due to significant profit growth likely impacting price by over 5%. Expected.
On 2026-04-28, announced Q1 2026 results with revenue of CNY 3.58 billion (+15.5% YoY) and net profit of CNY 335 million (+9.8% YoY). New orders grew over 30% YoY.
Received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an AI-powered coronary imaging platform.
Subsidiary clinical trial approval for SHR-2173 (myasthenia gravis) on April 28, 2026; low importance reflects expected >1% price impact. scheduled
The Board of Directors resolved on 2026-04-28 to terminate the post-IPO restricted share unit (RSU) plan and proposed the adoption of a new 2026 Share Plan, subject to shareholder approval. Low importance is assigned as administrative share plan changes typically have >=1% price impact.
On 2026-04-28, announced proposal to change the number of board members from nine to eight and revise the Articles of Association, subject to shareholder approval.
Announced Q1 2026 results on April 27, 2026, reporting a 45.1% YoY increase in revenue to RMB 726 million and a significant 91.2% reduction in net loss to RMB 20.56 million. The company achieved a net profit of RMB 43.44 million after excluding share-based payment expenses.
Announced Q1 2026 results on April 27, 2026, reporting a 28.8% YoY increase in revenue to RMB 12.44 billion and a 71.7% YoY increase in adjusted non-IFRS net profit to RMB 4.60 billion, beating expectations; high impact estimated due to significant profit growth, expected.
Announced on 2026-04-27 that its A-share listed subsidiary, CSPC Innovation Pharmaceutical, reported a net loss of RMB 93.85 million for Q1 2026; Medium importance estimated due to the substantial loss in a major subsidiary, with negative impact expected.
Q1 2026 results release scheduled for 2026-04-27. Analysts forecast revenue to increase 16.91% YoY to RMB 1.80 billion, but net profit to decrease 6.82% YoY to RMB 304 million. Importance is Medium as the profit decline is estimated to cause a 5-10% price impact, estimated.
Strategic cooperation MOU with UAE-based Arcera Life Sciences on April 27, 2026, for licensing and neuroscience innovation. Low importance estimated as MOUs typically have less than 5% price impact. Scheduled.
Presented positive preliminary clinical results for multiple pipeline candidates at the 2026 AACR Annual Meeting, including the PD-1/VEGF bispecific antibody JS207 for liver and colorectal cancer, and the EGFR/HER3 bispecific ADC JS212 for solid tumors.
On 2026-04-24, shareholders approved the 2026 Incentive Stock Program and Kevin Conroy was appointed to the Board of Directors, increasing the board size from twelve to thirteen members.
Alphabet announced its annual meeting for June 5, 2026, and filed proxy materials on April 24, 2026, including a proposal to add 200 million Class C shares to its 2021 Stock Plan. Low importance is estimated as this is a routine filing with expected <5% price impact, expected.
Medtronic disclosed in an 8-K filing on April 24, 2026, that it had identified unauthorized access to some of its IT systems, though no material impact is expected.
Announced on April 23, 2026, that shareholder Shanghai Tanying Investment Partnership plans to reduce its stake by up to 2% of the company's total share capital via block trades.
On April 23, 2026, Zacks Research analysts slightly lowered their full-year 2026 EPS forecast for the company to $4.40 from $4.42, forecasted.